Literature DB >> 10221376

Persistence with estrogen therapy in a postmenopausal Medicaid population.

J A Kotzan1, B C Martin, W E Wade.   

Abstract

We evaluated rates of persistence with estrogen replacement therapy in postmenopausal Georgia Medicaid recipients adjusted for age and race. Data files for 1992-1994 were examined to estimate 3-year conditional survival probabilities using the Kaplan-Meier model, and 3800 subjects were identified. Over 54% of women remained compliant over 29 months, and 17% continued therapy for the entire 35 months of observation. Kaplan-Meier predictors indicated that white women have a 70% chance of being compliant for 3 years, whereas black women have a 60% chance. Monthly discontinuation rates ranged from 1-1.5% after the second month of therapy. Younger, white women were the most likely to maintain and comply with therapy.

Entities:  

Mesh:

Year:  1999        PMID: 10221376     DOI: 10.1592/phco.19.4.363.30935

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  5 in total

1.  Assessing NSAID prescription use as a predisposing factor for gastroesophageal reflux disease in a Medicaid population.

Authors:  J Kotzan; W Wade; H H Yu
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

2.  Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosis.

Authors:  Markus J Seibel
Journal:  Clin Biochem Rev       Date:  2006-08

3.  Osteoporosis medications used by older African-American women: effects of socioeconomic status and psychosocial factors.

Authors:  Christine G Unson; Richard Fortinsky; Karen Prestwood; Susan Reisine
Journal:  J Community Health       Date:  2005-08

4.  Determinants of adherence to osteoporosis treatment in clinical practice.

Authors:  M Rossini; G Bianchi; O Di Munno; S Giannini; S Minisola; L Sinigaglia; S Adami
Journal:  Osteoporos Int       Date:  2006-03-15       Impact factor: 4.507

5.  Persistence with teriparatide in patients with osteoporosis: the UK experience.

Authors:  N K Arden; S Earl; D J Fisher; C Cooper; S Carruthers; M Goater
Journal:  Osteoporos Int       Date:  2006-07-06       Impact factor: 4.507

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.